Opus Genetics Inc expected to post a loss of 25 cents a share - Earnings Preview

Opus Genetics

08/11/2024 16:14

* Opus Genetics Inc  IRD.OQ   IRD.O  is expected to show a
fall in
quarterly revenue when it reports  results on November 11
(estimated) for the period ending September 30 2024
    * The Farmington Hills Michigan-based  company is expected
to
report a 80.8% decrease in revenue to $2.288 million from $11.94
million a year ago, according to the mean estimate from 4
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Opus Genetics Inc is for
a
loss of 25 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Opus
Genetics Inc
is $11.00​, above​ its last closing price of $1.09. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.28       -0.25      -0.30     Missed  -17.6
 Jan. 1 2024   -0.11       -0.13      -0.29     Missed  -116.4
 Dec. 31 2023  -0.03       -0.05      -0.21     Missed  -300​
 Sep. 30 2023  -0.24       -0.22      0.25      Beat    212.6
 ​​Jun.        -0.25       -0.23      -0.24     Missed  -6.2
 30 2023                                                
 Mar. 31 2023  -0.18       -0.15      -0.28     Missed  -81.8​
 Dec. 31 2022              0.97       1.58      Beat    63.3
 Sep. 30 2022  -0.29       -0.29      -0.22     Beat    23.7
 This summary was machine generated November 8 at 16:14 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)